阿加曲班联合双联抗血小板方案治疗急性脑梗死患者的疗效及对血清S100钙结合蛋白B和神经肽Y水平的影响OA
Efficacy of Argatroban Combined with Dual Antiplatelet Therapy in the Treatment of Acute Cerebral Infarction and the Level of Serum S100 Calcium-Binding Protein B and Neuropeptide Y
目的:观察阿加曲班联合双联抗血小板方案治疗急性脑梗死(ACI)患者的疗效及对血清 S100 钙结合蛋白 B(S100B)、神经肽 Y(NPY)水平的影响.方法:选取 2022 年 6 月～2023 年 6 月于某院收治的120 例 ACI 患者作为研究对象,采用随机数字表法分为对照组(双联抗血小板治疗)和观察组(阿加曲班联合双联抗血小板治疗),每组 60 例.比较治疗前后两组患者美国国立卫生研究院卒中量表(NIHSS)评分、Barthel 指数(BI)评分、全血高切黏度、血浆黏度、全血低切黏度、一氧化氮(NO)、内皮素-1(ET-1)、血清 S100B、NPY 水平,并比较两组患者临床疗效及不良反应发生情况.结果:治疗后,两组患者 NIHSS、全血高切黏度、血浆黏度、全血低切黏度、ET-1、血清 S100B和 NPY 水平均降低,且观察组低于对照组(P＜0.05);BI 和 NO 均升高,且观察组高于对照组(P＜0.05).观察组临床治疗总有效率(93.33%)高于对照组(73.33%,P＜0.05).两组患者不良反应总发生率比较均无统计学差异(连续性校正χ2=1.035,P=0.309).结论:阿加曲班联合双联抗血小板治疗ACI患者较佳,能有效改善患者神经功能、血管内皮功能,降低血液黏度,调节血清 S100B 和NPY 水平,改善日常生活能力,且安全性良好.
Objective:To observe the efficacy of argatroban combined with dual antiplatelet therapy in the treatment of acute cerebral infarction(ACI)and the levels of serum S100 calcium-binding protein B(S100B)and neuropeptide Y(NPY).Methods:A total of 120 patients with ACI who were admitted to our hospital from June 2022 to June 2023 were selected as the research subjects.They were randomly divided into the control group(receiving dual antiplatelet therapy)and the observation group(receiving argatroban combined with dual antiplatelet therapy),with 60 cases in each group.The National Institutes of Health Stroke Scale(NIHSS)scores,Barthel index(BI)scores,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,nitric oxide(NO),endothelin-1(ET-1),serum S100B and NPY levels were compared before and after treatment.The clinical efficacy and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,the NIHSS scores,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity ET-1,serum S100B and NPY levels in both groups decreased,and those in the observation group were lower than those in the control group(P<0.05).BI scores and NO levels increased,and those in the observation group were higher than those in the control group(P<0.05).The total effective rate of the observation group was higher than that of the control group(93.33%vs 73.33%,P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(continuity correction χ2=1.035,P=0.309).Conclusion:Argatroban combined with dual antiplatelet therapy is effective in the treatment of ACI,which can improve neurological function and vascular endothelial function,reduce blood viscosity,regulate serum S100B and NPY levels,and improve daily living ability with high safety.
张金苹;孙光明;代敏;张本骏;王甜甜;付记桐;李梦洋
郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000郑州市第七人民医院,郑州 450000
医药卫生
急性脑梗死阿加曲班双联抗血小板血清S100钙结合蛋白神经肽Y
acute cerebral infarctionagatrobandual antiplateletserum S100 calcium-binding protein Bneuropeptide Y
《中国合理用药探索》 2026 (4)
33-38,6
河南省医学科技攻关计划项目(LHGJ20220844)
评论